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Background/Aims: C-reactive protein (CRP) is an easily 
measured index of disease activity, but its ability to predict 
clinical course is controversial. We therefore designed a 
study to determine whether the CRP level at Crohn’s disease 
(CD) diagnosis is a valuable indicator of the disease pheno-
type, activity, and clinical course. Methods: We retrospec-
tively analyzed 705 CD patients from 32 institutions. The 
patients were classified into two groups according to CRP 
level. The patients’ demographic and clinical characteristics 
and their use of immunosuppressive or biological agents 
were recorded. Disease location and behavior, hospitaliza-
tion, and surgery were analyzed. Results: A high CRP was as-
sociated with younger age, steroid use, colonic or ileocolonic 
location, high CD activity index, and active inflammation at 
colonoscopy (p<0.001). As the disease progressed, patients 
with high CRP were more likely to exhibit strictures (p=0.027). 
There were significant differences in the use of 5-aminosali-
cylic acid, antibiotics, corticosteroids, azathioprine, and inflix-
imab (p<0.001, p<0.001, p<0.001, p<0.001, and p=0.023, 
respectively). Hospitalization was also more frequent in pa-
tients with high CRP. Conclusions: The CRP level at diagnosis 
is useful for evaluating the phenotype, activity, and clinical 
course of CD. Closer follow-up strategies, with early aggres-
sive treatment, could be considered for patients with high 
CRP. (Gut Liver 2016;10:595-603)
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INTRODUCTION
The clinical manifestation of Crohn’s disease (CD) is heteroge-
neous, and the natural course is unpredictable, with phenotypic 
changes over time.1-5 The development of prognostic markers 
would enable early treatment for severe CD. Although several 
clinical indices and serological and fecal markers, such as cal-
protectin, and genetic biomarkers, such as nucleotide-binding 
oligomerization domain-containing protein 2, have been evalu-
ated for the prediction of clinical course, a definitive predictive 
marker has not been fully established.6-10 
C-reactive protein (CRP) is a surrogate marker of acute in-
flammation induced by infection, stress, tissue necrosis, trauma, 
and malignancies.11 CRP is synthesized principally by hepato-
cytes in response to stimulation by interleukin-1, interleukin-6 
(IL-6), and tumor necrosis factor-α (TNF-α).12 Recent studies 
have suggested that CRP is also produced by peripheral lympho-
cytes, inflamed kidneys, alveolar macrophage, and adipocytes in 
quantities insufficient to affect plasma CRP levels.13,14 CRP func-
tions independent of physiological and pathological conditions 
and plasma CRP levels in patients with CD.11 Therefore, CRP 
production by the liver may be the only factor determining the 
plasma CRP level, suggesting the potential of CRP as a valuable 
marker to diagnose and monitor CD patients.
Estimating CRP may be useful to evaluate disease activity 
because it requires an inexpensive and easily accessible test; in 
addition, compared to other inflammatory markers, CRP has a 
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short half-life of 19 hours.15 Several studies have demonstrated 
that CRP levels are associated with the clinical, radiographic, en-
doscopic, and histological activity in CD.16-18 However, whether 
CRP levels can predict the clinical course is not known. Higher 
CRP levels at the time of diagnosis or relapse have been associ-
ated with more frequent and severe short- and medium-term 
relapses.11,19 A retrospective study from Portugal reported that 
high CRP in CD predicts nonresponse to infliximab.20 However, 
these data were from a single-center study with a small number 
of subjects, thus limiting the generalizability of the results. There 
is lack of reports that provide conclusive evidence for predicting 
aggressive clinical course and establishing treatment plan.
We therefore conducted a multicenter cohort study of a large 
number of CD subjects to determine if the CRP level at diagnosis 
is a valuable predictive marker of disease phenotype, activity, 
and clinical course.
MATERIALS AND METHODS
1. Study population
We reviewed a retrospective clinical database that included 
patients diagnosed with CD between July 1982 and December 
2008 who were enrolled in the Crohn’s Disease Clinical Network 
and Cohort (CONNECT) study. The gastroenterology clinics of 
32 institutions in Korea participated in this cohort study, which 
was performed by the Korean Association for the Study of In-
testinal Diseases.21,22 The institutions comprised 30 university 
hospitals and two community hospitals. Patients were eligible 
for the study if they had a measurable CRP level at the time of 
diagnosis, they did not have coexisting infectious colitis, they 
were followed up for longer than 6 months (to identify long-
term clinical outcomes), and the status of their CD was evalu-
ated before enrollment and at the end of the study. We excluded 
patients with incomplete clinical data (n=100), those for whom 
CRP level at diagnosis was unavailable (n=490), and those with 
lack of medical record from the referral hospitals (n=79), and 
those who were followed up for less than 6 months (n=8).
Patients were classified into two groups based on CRP >20 
mg/L and ≤20 mg/L. 
The diagnosis of CD was confirmed in all cases by previously 
established guidelines based on clinical history, endoscopic and 
radiological examinations, and histopathological findings.23 
2. Data collection and outcome measurement 
Clinical data at initial presentation of CD and subsequent 
follow-up visits were retrieved for analysis from the electronic 
medical record system. The collected data included age, gender, 
length of follow-up, disease location, and behavior at the time 
of diagnosis according to the Montreal classification. Disease 
location at final follow-up was categorized as colorectum, jeju-
num, ileum, or esophagogastroduodenum. The development of 
intestinal strictures, perianal fistula, and other fistulas and the 
time required to develop these lesions were assessed. Other fis-
tulas were defined as abnormal tracks formed between the gut 
and gut, skin, an abscess cavity, or other hollow structures in-
cluding the bladder, urethra, uterus, or vagina. We also recorded 
complications including abscesses, perforations, intestinal can-
cers, and primary sclerosing cholangitis. 
Clinical disease activity at the time of diagnosis was assessed 
using the Crohn’s disease activity index (CDAI), with a score of 
>150 indicating active disease. Among the typical endoscopic 
features of CD, a cobblestone appearance and longitudinal ul-
cers were reviewed because these lesions can indicate increased 
CD activity. We recorded medication use during follow-up 
period, including 5-aminosalicylic acid (5-ASA), antibiotics, 
budesonide, and corticosteroids. The use of immunosuppres-
sants, including azathioprine, 6-mercaptopurine, methotrexate, 
and TNF blockers such as infliximab and adalimumab, was also 
reviewed. Time from CD diagnosis to first use of azathioprine or 
TNF blockers was calculated to assess the length of time before 
these drugs were required to treat severe disease. Disease-related 
hospitalization (including readmissions) and surgery data were 
assessed because these can indicate a more severe course in 
CD.24 The collected data regarding hospitalization included the 
total number of hospital admissions and the readmission rate. 
In this analysis, readmission was defined as two or more admis-
sion of a discharged patient for further inpatient care as a new 
episode. 
The proportion of patients who underwent surgery was record-
ed, and additional data including the total number of surgeries, 
resurgeries, and survival rates were obtained. These patients 
were analyzed according to the causative lesion for surgery or 
resurgery: intestinal or perianal lesion. Resurgery was defined as 
surgery at the same lesion site or at another site for a relapsed 
or uncontrolled lesion or to repair temporary structures from a 
previous surgery such as ileostomy repair. This study protocol 
was reviewed and approved by the Institutional Review Board 
of each participating medical center.
3. Statistical analysis
Continuous variables are presented as means±standard devia-
tion when appropriate. Categorical variables were summarized 
as frequency and percentage. We performed univariate analyses 
using an independent t-test for continuous variables and the 
Pearson chi-square test, Fischer exact test, or linear by linear 
association for categorical variables. Kaplan-Meier method and 
log-rank test were used to determine the cumulative probability 
of stricture, perianal fistula, other fistula, use of azathioprine 
and TNF blocker, and risk of surgery according to the CRP level 
at diagnosis. Binary logistic regression analysis was performed 
using a forward stepwise selection method to evaluate risk fac-
tors affecting hospital admission of patients with CD. A multi-
variate analysis was performed if the univariate analysis yielded 
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p<0.25. A p-value <0.05 was considered to indicate statistical 
significance. All analyses were performed using IBM SPSS ver-
sion 20.0 (IBM Corp., Armonk, NY, USA).
RESULTS
1. Demographic and clinical characteristics of patients 
A total of 705 CD patients with measurable CRP levels were 
ultimately included in this analysis. The CRP value at the time 
of diagnosis was used as the index CRP level. The patients were 
classified into two groups by their index CRP level, with a cut-
off at 20 mg/L: 373 had a CRP >20, and 332 had a CRP ≤20 
mg/L. The patients were 7 to 77 years of age at the time of CD 
diagnosis, and the mean follow-up duration was 7.1 years. The 
demographic, clinical and laboratory details of the two groups 
are summarized in Table 1. There were no significant differences 
between the groups in gender, family history of inflammatory 
bowel disease (IBD), history of perianal disease, or history of 
taking anti-tuberculosis medications. Body mass index (BMI) 
was significantly lower in the high CRP group. Patients with 
high CRP were younger at diagnosis than those with low CRP 
(p<0.001) and had lower hemoglobin, higher CDAI, and elevated 
erythrocyte sedimentation rate (ESR). There was a significant 
difference in lesion location at time of diagnosis (p<0.001). Le-
Table 1. Baseline Characteristics of Patients with Crohn’s Disease ac-
cording to the C-Reactive Protein Level at Diagnosis
Variable
CRP >20 
(n=373)
CRP ≤20 
(n=332)
p-value
Age, yr 25.4±10.1 28.6±14.2 <0.001
Sex, male/female 285/88 238/94 0.153
Time to follow-up, mo 86.4±44.1 83.5±43.9 0.379
BMI, kg/m2 19.1±3.3 20.9±4.2 <0.001
Smoking status 0.020
    Never smoker 245 (77.8) 168 (70.0)
    Current smoker 46 (14.6) 36 (15.0)
    Ex-smoker 16 (5.1) 31 (12.9)
    Stop smoking after treatment 8 (2.5) 5 (2.1)
Family history of IBD 9 (2.4) 7 (2.1) 0.447
Hb, g/dL 11.9±1.9 12.8±2.1 <0.001
Hct, % 36.0 38.1 <0.001
ESR, mm/hr 47.5±29.2 23.6±21.5 <0.001
CDAI at diagnosis 217.5±110.2 164.6±89.2 <0.001
Location at diagnosis* <0.001
    L1 (ileal) 51 (17.5) 91 (32.9)
    L2 (colonic) 71 (24.4) 48 (17.3)
    L3 (ileocolonic) 164 (56.4) 134 (48.4)
    L4 (upper GI) 5 (1.7) 4 (1.4)
Behavior at diagnosis* 0.503
    B1 (inflammatory) 176 (71.3) 193 (72.6)
    B2 (stricturing) 32 (13.0) 39 (14.7)
    B3 (penetrating) 39 (15.8) 34 (12.8)
Steroid use at diagnosis 154 (41.2) 84 (25.3) <0.001
History of anti-TB medication 67 (18.0) 70 (21.1) 0.296
History of perianal disease 108 (29.0) 81 (24.4) 0.173
Data are presented as mean±SD or number (%).
CRP, C-reactive protein; BMI, body mass index; IBD, inflammatory 
bowel disease; Hb, hemoglobin; Hct, hematocrit; ESR, erythrocyte 
sedimentation rate; CDAI, Crohn’s disease activity index; GI, gastro-
intestinal; TB, tuberculosis.
*Location and behavior at the time of diagnosis were unavailable in 
137 and 192 patients, respectively. 
Table 2. Disease Manifestation according to the C-Reactive Protein 
Level at Diagnosis
Variable
CRP >20
 (n=373)
CRP ≤20
(n=332)
p-value
Involved location 
    Colorectum 322 (86.3) 222 (66.9) <0.001
    Jejunum 49 (13.1) 61 (18.4) 0.651
    Ileum 310 (83.1) 270 (81.3) 0.917
    Esophagogastroduodenum 36 (9.7) 27 (8.1) 0.324
Endoscopic findings
    Longitudinal ulcer 255 (68.4) 148 (44.6) <0.001
    Cobblestone appearance 160 (42.9) 57 (17.2) <0.001
Histological finding
    Granuloma 148 (39.7) 110 (33.1) 0.657
Stricture 0.027
    Yes, at diagnosis 49 (13.5) 33 (10.0)
    Yes, during disease course 46 (12.7) 29 (8.8)
Perianal fistula 0.137
    Yes, at diagnosis 105 (28.6) 77 (23.3)
    Yes, during disease course 35 (9.5) 28 (8.5)
Other fistula 0.145
    Yes, at diagnosis 27 (7.4) 10 (3.1)
    Yes, during disease course 28 (7.7) 22 (6.7)
Abdominal abscess 0.068
    Yes, at diagnosis 20 (5.5) 14 (4.3)
    Yes, during disease course 31 (8.5) 17 (5.3)
Perforation 0.103
    Yes, at diagnosis 14 (3.8) 14 (4.3)
    Yes, during disease course 6 (1.6) 12 (3.7)
Intestinal cancer* 0.659
    Yes, at diagnosis 1 (0.3) 3 (0.9)
    Yes, during disease course 2 (0.5) 0 
Primary sclerosing cholangitis 0.472
    No 364 (100) 324 (99.7)
    Yes, during disease course 0 1 (0.3)
Data are presented as number (%).
CRP, C-reactive protein.
*Includes small bowel and colon cancer.
598  Gut and Liver, Vol. 10, No. 4, July 2016
sions in the high CRP group more frequently involved the colon 
(24.4%) and ileocolon (56.4%), while the low CRP group had 
more frequent terminal ileal (32.9%) and ileocolonic (48.4%) 
involvement. The CRP level did not distinguish disease behavior 
(p=0.503); the nonstricturing and nonpenetrating phenotype (B1) 
was the most frequent disease behavior type in both groups. 
Location and behavior at diagnosis were unavailable in 137 and 
192 patients, respectively. Corticosteroid use at the time of diag-
nosis was significantly higher in the high CRP group compared 
with the low CRP group (41.2% vs 25.3%, p<0.001).
2. Disease manifestation 
Colorectal involvement during the course of the disease was 
more frequent in the high CRP group (p<0.001). There were no 
statistically significant differences in jejunal, ileal, and esopha-
gogastroduodenal involvement between the two groups. Endo-
scopic findings of longitudinal ulcer and cobblestone appear-
ance were more frequent in the high CRP group (p<0.001 and 
p<0.001, respectively). Stricture during the course of the disease 
was more frequent in the high compared to the low CRP group 
(p=0.027). There were no significant differences in the develop-
ment of fistulas, intestinal perforations, abscesses, intestinal 
cancers, or primary sclerosing cholangitis between the groups 
(Table 2). Using the Kaplan-Meier method, significant difference 
was found in the cumulative probability of stricture according 
to the CRP level at diagnosis (p=0.019). However, cumulative 
probability of perianal fistula and other fistula did not differ 
(Fig. 1).
3. Use of medications 
Medication use was investigated according to the index 
CRP level (Table 3). There were significant differences between 
the two groups in the use of 5-ASA-based agents, antibiotics, 
corticosteroids, azathioprine, and biological agents (p<0.001, 
p<0.001, p<0.001, p<0.001, and p=0.042, respectively). Of these 
medications, more subjects with high CRP had used infliximab 
(p=0.023), but there was no significant difference in adalim-
umab use between the two groups. The cumulative use of aza-
thioprine and TNF blocker was significantly higher in high CRP 
group than in low CRP group (Fig. 2).
4. Hospital admission, surgery, and survival 
The total numbers of hospital admissions and readmissions 
were also analyzed according to the index CRP level. The total 
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Fig. 1. (A) Kaplan-Meier curve showing the cumulative probability of 
stricture according to the C-reactive protein (CRP) level (log-rank test, 
p=0.019). (B) Kaplan-Meier curve showing the cumulative probability 
of perianal fistula according to the CRP level (log-rank test, p=0.157). 
(C) Kaplan-Meier curve showing the cumulative probability of other 
fistula according to the CRP level (log-rank test, p=0.086).
Kwon JH, et al: Clinical Course Based on the C-Reactive Protein in Crohn’s Disease  599
number of hospital admissions differed significantly between 
the patients with high or low CRP (3.2±4.2 vs 2.3±3.7, p=0.011). 
In addition, the rate of readmission was higher in the high CRP 
group (p=0.048). Regarding CD-related surgeries, there were no 
significant differences in the total number of surgeries or the 
proportion of patients who underwent surgery for intestinal 
or perianal lesions between the two groups, nor did they differ 
in the proportion of repeat surgeries for intestinal or perianal 
lesions. The cumulative risk of surgery and resurgery did not 
differ according to the CRP level at diagnosis (Fig. 2). Only two 
patients died during the follow-up period: one from cardiac ar-
rest of unknown cause and the other from intestinal bleeding 
associated with CD (Table 4).
5. Predictors of hospitalization
We performed logistic regression analysis to identify factors 
that predicted hospitalization (Table 5). In univariate analysis, 
high index CRP, younger age, use of a TNF blocker, high CDAI 
at diagnosis, and a stricturing phenotype were all significant 
risk factors for hospitalization. Variables including high CRP 
Fig. 2. (A) Kaplan-Meier curve showing the cumulative use of azathioprine according to the C-reactive protein (CRP) level (log-rank test, p<0.001). 
(B) Kaplan-Meier curve showing the cumulative use of a tumor necrosis factor blocker according to the CRP level (log-rank test, p=0.041). (C) 
Kaplan-Meier curve showing cumulative risk of surgery according to the CRP level (log-rank test, p=0.067). (D) Kaplan-Meier curve showing cu-
mulative risk of resurgery according to the CRP level (log-rank test, p=0.489).
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Table 3. Use of Medications according to the C-Reactive Protein Level 
at Diagnosis
Variable
CRP >20 
(n=373)
CRP ≤20
(n=332)
p-value
Use of medications
    5-ASA 368 (98.7) 309 (93.1) <0.001
    Antibiotics 239 (64.1) 153 (46.1) <0.001
    Budesonide 42 (11.3) 32 (9.6) 0.494
    Corticosteroid 263 (70.5) 164 (49.7) <0.001
    Azathioprine 281 (75.3) 194 (58.4) <0.001
    MTX  4 (1.1)  6 (1.8) 0.407
    Infliximab 102 (27.4) 66 (19.9) 0.023
    Adalimumab 21 (5.6) 15 (4.5) 0.516
    TNF blocker 111 (29.8) 76 (22.9) 0.042
TPN 77 (20.6) 59 (17.8) 0.796
Time to use of azathioprine, mo 28.8±34.0 28.6±31.3 0.950
Time to use of TNF blockers, mo 52.2±41.1 61.8±43.1 0.114
Data are presented as number (%) or mean±SD.
CRP, C-reactive protein; ASA, aminosalicylic acid; MTX, methotrex-
ate; TNF, tumor necrosis factor; TPN, total parenteral nutrition.
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(hazard ratio [HR], 2.03; 95% confidence interval [CI], 1.10 to 
3.82; p=0.028), use of a TNF blocker (HR, 22.90; 95% CI, 3.10 to 
172.10; p=0.002), and a stricturing phenotype (HR, 11.31; 95% 
CI, 2.62 to 48.81; p=0.001) were also significant risk factors for 
hospitalization in the multivariate analysis.
DISCUSSION
In this study, CD patients with CRP >20 mg/L were more like-
ly to be younger and exhibit colonic or ileocolonic involvement. 
The CRP level was a useful index of clinical and endoscopic dis-
ease activity. During follow-up, high CRP was associated with 
more aggressive treatments, such as immunosuppressants and 
biological agents, and with the total number of hospital admis-
sions and readmissions. 
CRP was described as a marker for the differential diagnosis 
of CD and ulcerative colitis,15 and the association between CRP 
and disease activity has been investigated. Several recent studies 
have reported a correlation between the index CRP and clini-
cal relapses, the subsequent need for aggressive treatment, and 
response to treatment.19,25 However, research supporting the CRP 
level at the time of diagnosis as a predictor of the clinical course 
is lacking.
In a recent study by the Brisbane IBD research group, the 
low CRP group had a strikingly lower BMI and more pure ileal 
disease (predisposing them to intestinal resections) than the 
high CRP group.26 A retrospective study in Germany also re-
ported disease with an exclusively ileal distribution in the low 
CRP group.27 Although we could not reproduce the correlation 
between a low BMI and prior intestinal resection, we confirmed 
that patients with low CRP tend to develop ileal disease, while 
those with high CRP have a higher frequency of colonic in-
volvement. Our results are consistent with those of previous 
studies.16,18,28 Although the exact mechanism underlying the pre-
dominance of ileal lesions in the low CRP group is not under-
stood, a study has indicated that ileal disease has a tendency to 
evolve more locoregional inflammatory disease, as evidenced by 
a high rate of fat wrapping in surgical specimens, than systemic 
disease and, consequently, does not elevate CRP.26 
Studies of the Montreal classification of CD behavior based 
on the CRP level have yielded conflicting results. In a prospec-
tive population-based study, noninflammatory behavior includ-
ing stricturing or penetrating disease was associated with a 
high CRP at the time of diagnosis.25 By contrast, a retrospective 
database-based study concluded that there was no significant 
difference in disease behavior based on the index CRP level dur-
ing a clinical relapse.19 However, little information is available 
regarding changes in disease behavior during the course of the 
disease among these patients. In our study, there was no signifi-
cant difference in disease behavior between the two groups at 
the initial presentation of CD, and inflammatory disease was the 
predominant phenotype in both groups. In addition, we found 
that intestinal strictures occurred more frequently in high CRP 
patients throughout the disease course. Our findings suggest 
that high CRP patients have a higher likelihood of fibrostenotic 
changes because they have a chronic inflammatory profile. We 
therefore believe that CRP can be a valuable tool to predict fur-
ther stricture formation, which is a major indication for surgery.
We also observed that high CRP was significantly correlated 
with a cobblestone appearance and longitudinal ulcers at colo-
noscopy, which suggest active inflammation. In addition, the 
CDAI score of high CRP patients was higher than the score of 
those with low CRP. These results correspond with those of a 
Table 4. Hospital Admission, Surgery, and Survival according to the 
C-Reactive Protein Level at Diagnosis
Variable
CRP >20 
(n=373)
 CRP ≤20 
(n=332)
p-value
Total no. of admission 3.10±4.20 2.30±3.70 0.011
Readmission 193 (51.7) 147 (44.3) 0.048
Patients performed surgery 179 (48.0) 146 (44.0) 0.286
Total no. of surgeries 1.50±0.84 1.50±0.81 0.823
Surgery of intestinal lesion  82 (22.0) 74 (22.3) 0.922
Surgery of perianal lesion 109 (29.2) 76 (22.9) 0.056
Resurgery of intestinal lesion 15 (4.0)  9 (2.7) 0.338
Resurgery of perianal lesion 26 (7.0) 25 (7.5) 0.775
Dead  1 (0.3)  1 (0.3) 0.932
Data are presented as mean±SD or number (%).
CRP, C-reactive protein.
Table 5. Multivariate Logistic Regression Analysis to Evaluate Potential Predictors for Hospitalization 
Variable
   Univariate analysis  Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
CRP, >20 mg/L 2.30 1.63–3.26 <0.001 2.03 1.10–3.82 0.028
Age 0.98 0.97–0.99 0.004 0.99 0.97–1.02 0.761
Use of TNF blocker 7.16  3.88–13.23 <0.001  22.90  3.10–172.10 0.002
CDAI at diagnosis 1.00 1.00–1.01 0.021 1.00  1.00–1.01 0.255
Stricturing phenotype 3.86 2.23–6.69 <0.001  11.31  2.62–48.81 0.001
HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; TNF, tumor necrosis factor; CDAI, Crohn’s disease activity index.
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retrospective study of 147 American patients that demonstrated 
that an elevated CRP was associated with clinical disease activ-
ity, endoscopic inflammation, and several other IBD biomark-
ers.16 
CRP can be used to predict subsequent need for azathioprine 
and biological agents as well as clinical relapse.19 A retrospec-
tive study in the Netherlands provided additional evidence for 
the role of CRP in predicting a more severe clinical course of 
CD, such as number of relapses, severity of relapse, and cumu-
lative days of prednisone use.25 In accord with previous stud-
ies, we determined that patients with high CRP received more 
aggressive medical treatment, such as immunosuppressants or 
biological agents. Our multivariate analysis also indicated that 
a high CRP level is an independent predictor for hospitalization. 
Interestingly, the CRP groups did not differ in their need for sur-
gery or repeat surgery. These results coincide well with those of 
a previous study that reported that patients with low CRP more 
often have purely ileal disease, with an increased requirement 
for intestinal resection.26 Accordingly, we can postulate that the 
surgery rate in patients with low CRP would be similar to that 
of those with a high CRP, in whom more aggressive treatment 
would be required.
In the present study, we observed a correlation of CRP levels 
with clinical progression to severe disease. Although the precise 
mechanisms underlying this correlation have not been fully 
elucidated, some plausible explanation for these results can be 
inferred from some published reports. Mesenteric fat, rather 
than the intestinal wall, is likely important for the production of 
CRP in CD patients.29 The mesenteric fat hyperplasia observed in 
CD but not UC has been suggested to contribute to the synthesis 
of inflammatory mediators such as TNF-α and IL-6, which pro-
mote damage to the intestinal mucosa. In addition, mesenteric 
fat hyperplasia could impair gut barrier function by disturbing 
innate immunity to the gut flora.30 Based on these findings, 
the elevation of CRP at baseline could reflect the degree of 
mesenteric fat hyperplasia. Accordingly, increased production 
of inflammatory cytokines via the accumulation of mesenteric 
adipocytes might induce a severe, ongoing, inflammatory pro-
cess, and direct assessment of this inflammatory activity could 
facilitate the prediction of a more severe clinical course. 
Several studies have presented different CRP cutoff values for 
CD patients,19,25,31 but a definitive cutoff value for predicting dis-
ease activity and clinical course has not been established. In a 
study of French patients, high CRP (>20 mg/L) was emphasized 
as a valuable diagnostic marker for predicting a van Hees index 
≥150.32 The GETAID group emphasized that CRP >20 mg/L and 
ESR >15 mm/hr were the only meaningful laboratory markers 
predictive of relapse.31 Furthermore, a multicenter randomized 
controlled study indicated that high CRP (>20 mg/L) was corre-
lated with relapse after azathioprine withdrawal.33 These results 
determined our selection of 20 mg/L as the optimal CRP cutoff 
value for categorizing the disease manifestations and clinical 
course of CD. 
This study improves upon previous studies by employing 
a multicenter cohort from 32 institutions of CD patients with 
measurable CRP. This design minimizes bias that might arise 
from a single center case-control study. We also enrolled a sig-
nificant proportion of potential cases, ultimately including 705 
patients and thereby substantially increasing the statistical pow-
er. Furthermore, uniform findings based on the CRP level were 
reproduced in this study despite the heterogeneity of the studied 
population. The classification of disease phenotype, activity and 
clinical course by CRP level may therefore be applicable to the 
patients with CD in clinical practice. 
Our study is limited by its retrospective nature, which limits 
our ability to provide a causal explanation for the relationship 
between CRP levels and clinical outcomes. 
This study includes missing values on potentially important 
covariates, which could be unavoidable in retrospective and 
observational study. However, unavailable data is mostly due 
to insufficient data collection and work-up or loss to follow-
up before electronic medical record was introduced in the early 
2000s. In addition, there is a possibility of poor quality as-
surance concerning admission, treatment, and follow-up and 
patient enrollment with relatively severe disease state due to 
characteristics of participating secondary or tertiary care center, 
which could limit reliability of the study. However, these po-
tential confounders were minimized by the retrieval of clinical 
data from electronic medical record systems at all participating 
hospitals and accurate recording of the time to occurrence of 
any event or use of medication. Unfortunately, we could not 
investigate clinical data on the frequency or severity of relapses, 
improvement of subjective symptoms, and treatment response, 
particularly for biological agents, due to the lack of medical re-
cords and the observational study design. In conclusion, CRP at 
the time of diagnosis appears to be useful in predicting disease 
phenotype, clinical and endoscopic activity, and the clinical 
course of CD. Early aggressive treatment with intensive follow-
up management strategy may be warranted in patients with 
high CRP. In addition, the integration of CRP levels with other 
predictive indices will improve the reliability of the identifica-
tion of the natural history of CD. A further prospective study 
that includes a large number of subjects could provide definitive 
evidence of the correlation of CRP levels with multiple clinical 
outcomes.
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